We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmaceuticals – Kenya.
- Abstract
US pharmaceutical company Moderna has been accused by the Africa Centres for Disease Control and Prevention (Africa CDC) of jeopardizing the African Union's plans to produce 60% of the continent's vaccines and medical products by 2040. Moderna recently announced the closure of its operations in Kenya, citing a decline in demand for Covid-19 vaccines in Africa. This decision also undermines Kenya's President William Ruto's plan to position the country as a regional hub for vaccine and pharmaceutical production. Moderna is not the only pharmaceutical company to leave Kenya, as German pharmaceutical Bayer and Britain's GlaxoSmithKline have also outsourced their operations. The European Commission had previously promised support for an African Medicines Agency and pharmaceutical sector, but little progress has been made on these plans.
- Subjects
KENYA; DRUGS; COVID-19 pandemic; PHARMACEUTICAL industry; MEDICAL supplies
- Publication
Africa Research Bulletin: Economic, Financial & Technical Series, 2024, Vol 61, Issue 4, p24720C
- ISSN
2053-227X
- Publication type
Article
- DOI
10.1111/j.1467-6346.2024.11639.x